-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ever recorded- TUCSON, Ariz., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, proudly marks a new milestone in the fi ...

Core Viewpoint - Picard Medical, Inc. will showcase its SynCardia Total Artificial Heart (STAH) at the American Heart Association (AHA) annual meeting, highlighting its status as the most widely used and studied artificial heart globally [1][5]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona. It is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [5]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [5]. - Over 2,100 implants of the STAH have been performed in hospitals across 27 countries, establishing it as the most widely used and extensively studied artificial heart in the world [5]. Event Participation - The AHA annual meeting will take place from November 7 to 10 in New Orleans, Louisiana, where Picard Medical will exhibit at booth 3408 [1]. - The CEO of Picard Medical expressed excitement about sharing the latest developments regarding the STAH and engaging with physicians and attendees about patient eligibility and clinical data [2]. AHA Overview - The American Heart Association (AHA) is the oldest and largest voluntary organization in the U.S. dedicated to combating heart disease and stroke, with over 35 million volunteers and supporters [4]. - The AHA has invested more than $6 billion in cardiovascular research, making it the largest non-profit funding source for cardiovascular and cerebrovascular disease research after the federal government [4].

Core Viewpoint - Picard Medical, Inc. reported significant financial growth driven by strong sales of its SynCardia total artificial heart, achieving over 200% revenue growth year-over-year and successfully completing an IPO that raised $19.5 million to support future developments [2][3][7]. Financial Performance - **Second Quarter 2025 Results**: Revenue increased by 207% to $2.13 million from $0.69 million in Q2 2024, primarily due to higher U.S. product sales. Gross loss improved by 67% to $0.13 million, while operating loss decreased by 8% to $3.52 million. Net loss was $6.72 million, up from $4.06 million in the prior year, influenced by higher non-cash debt discount and derivative losses [3][5]. - **Year-to-Date 2025 Results**: For the first half of 2025, revenue rose by 3% to $2.74 million compared to $2.67 million in the same period of 2024. Gross loss was $0.49 million, contrasting with a gross profit of $0.43 million in the first half of 2024. Operating loss widened by 19% to $6.77 million, and net loss increased to $12.29 million from $6.01 million in the prior year, again due to higher non-cash debt discount and derivative losses [4][5]. Company Outlook - Following the successful IPO, the company anticipates funding operations into 2026 and aims to enhance the adoption of its total artificial heart while advancing its next-generation fully implantable heart platform, the Emperor [6]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for its SynCardia Total Artificial Heart, the only commercially available total artificial heart technology in the U.S. and Canada, with over 2,100 implants performed globally [7][8].